Search
Kiora Pharmaceuticals Inc
KPRXAdd to Watchlist
2.550USD
+0.050+2.00%
Close 07-24 16:00（ET）Quotes delayed by 15 min
11.30MMarket Cap
LossP/E TTM
More Details of Kiora Pharmaceuticals Inc Company
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
Kiora Pharmaceuticals Inc Info
Ticker SymbolKPRX
Company nameKiora Pharmaceuticals Inc
IPO dateFeb 13, 2015
CEOStrem (Brian M)
Number of employees12
Security typeOrdinary Share
Fiscal year-endFeb 13
Address169 Saxony Rd.
CityENCINITAS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92024
Phone18582249600
Websitehttps://kiorapharma.com/
Ticker SymbolKPRX
IPO dateFeb 13, 2015
CEOStrem (Brian M)
Company Executives of Kiora Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Melissa Tosca, CPA
Ms. Melissa Tosca, CPA
Chief Financial Officer
Chief Financial Officer
26.99K
-3.37%
Ms. Erin Parsons
Ms. Erin Parsons
Independent Director
Independent Director
5.26K
--
Mr. Praveen Tyle, Ph.D.
Mr. Praveen Tyle, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.01K
--
Mr. Aron Shapiro
Mr. Aron Shapiro
Director
Director
3.00K
--
Ms. Lisa Walters-Hoffert
Ms. Lisa Walters-Hoffert
Independent Director
Independent Director
1.25K
--
Dr. Brian M. Strem, Ph.D.
Dr. Brian M. Strem, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Eric J. Daniels, M.D.
Dr. Eric J. Daniels, M.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. David A. Hollander, M.D.
Dr. David A. Hollander, M.D.
Independent Director
Independent Director
--
--
Mr. Carmine Stengone
Mr. Carmine Stengone
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Melissa Tosca, CPA
Ms. Melissa Tosca, CPA
Chief Financial Officer
Chief Financial Officer
26.99K
-3.37%
Ms. Erin Parsons
Ms. Erin Parsons
Independent Director
Independent Director
5.26K
--
Mr. Praveen Tyle, Ph.D.
Mr. Praveen Tyle, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.01K
--
Mr. Aron Shapiro
Mr. Aron Shapiro
Director
Director
3.00K
--
Ms. Lisa Walters-Hoffert
Ms. Lisa Walters-Hoffert
Independent Director
Independent Director
1.25K
--
Dr. Brian M. Strem, Ph.D.
Dr. Brian M. Strem, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
FAQs
Who are the top five shareholders of Kiora Pharmaceuticals Inc?
The top five shareholders of Kiora Pharmaceuticals Inc are: Ms. Melissa Tosca, CPA
How many institutions hold shares of Kiora Pharmaceuticals Inc (KPRX)?
As of 2026Q1, 43 institutions hold shares of Kiora Pharmaceuticals Inc, with a combined market value of approximately 843.30K, accounting for 19.03% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -588961.00.